Kexing Biopharm Co., Ltd. (SHA:688136)
China
· Delayed Price · Currency is CNY 25.89
-2.75 (-9.60%)
Apr 29, 2026, 3:00 PM CST
Kexing Biopharm Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Net Income | 152.74 | 31.48 | -190.29 | -90.3 | 96.46 | Upgrade
|
| Depreciation & Amortization | 109.01 | 99.03 | 88.26 | 71.04 | 49.88 | Upgrade
|
| Other Amortization | 6.06 | 7.69 | 11.01 | 9.97 | 6.75 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0.95 | -0.08 | -0.28 | -1.46 | 0.47 | Upgrade
|
| Asset Writedown & Restructuring Costs | -76.34 | 0.17 | 1.6 | 0.42 | 2.94 | Upgrade
|
| Loss (Gain) From Sale of Investments | -30.77 | 19.65 | -7.17 | 1.52 | -56.65 | Upgrade
|
| Provision & Write-off of Bad Debts | - | 1.4 | -3.13 | 0.17 | -1.77 | Upgrade
|
| Other Operating Activities | 43.57 | 42.81 | 35.57 | 22.97 | 10.99 | Upgrade
|
| Change in Accounts Receivable | -224.91 | -228.07 | -70.17 | -85.91 | -66.53 | Upgrade
|
| Change in Inventory | 0.25 | 45.89 | -14.87 | -35.26 | -59.28 | Upgrade
|
| Change in Accounts Payable | 92.91 | 69.46 | 124.93 | 60.42 | 111.97 | Upgrade
|
| Change in Other Net Operating Assets | 5.18 | 4.37 | 7.72 | 7.85 | - | Upgrade
|
| Operating Cash Flow | 86.03 | 106.67 | -87.14 | -85.89 | 94.01 | Upgrade
|
| Operating Cash Flow Growth | -19.35% | - | - | - | -11.25% | Upgrade
|
| Capital Expenditures | -83.63 | -93.99 | -191.2 | -399.17 | -371.98 | Upgrade
|
| Sale of Property, Plant & Equipment | 1.17 | 0.04 | - | 1.78 | 64.47 | Upgrade
|
| Cash Acquisitions | -1.07 | - | - | - | - | Upgrade
|
| Divestitures | 13.5 | - | - | - | - | Upgrade
|
| Investment in Securities | -7.95 | -8.37 | 12.05 | - | -200 | Upgrade
|
| Other Investing Activities | 14.22 | -1.8 | 22.9 | 15.94 | 15.01 | Upgrade
|
| Investing Cash Flow | -63.76 | -104.13 | -156.25 | -381.45 | -492.5 | Upgrade
|
| Long-Term Debt Issued | 916.43 | 627.66 | 420.63 | 1,016 | 505.52 | Upgrade
|
| Long-Term Debt Repaid | -732.42 | -569.77 | -371.69 | -591.08 | -284.65 | Upgrade
|
| Net Debt Issued (Repaid) | 184.01 | 57.88 | 48.93 | 424.72 | 220.88 | Upgrade
|
| Issuance of Common Stock | 19.25 | 6.96 | 7.82 | - | - | Upgrade
|
| Repurchase of Common Stock | - | -31.13 | - | - | - | Upgrade
|
| Common Dividends Paid | -57.38 | -43.63 | -45.41 | -53.63 | -28.39 | Upgrade
|
| Other Financing Activities | -72.56 | -1 | 4.91 | - | -5.55 | Upgrade
|
| Financing Cash Flow | 73.31 | -10.91 | 16.25 | 371.1 | 186.94 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.21 | 1.39 | 3.09 | 5.43 | -2.07 | Upgrade
|
| Net Cash Flow | 95.37 | -6.98 | -224.04 | -90.81 | -213.61 | Upgrade
|
| Free Cash Flow | 2.4 | 12.68 | -278.34 | -485.06 | -277.97 | Upgrade
|
| Free Cash Flow Growth | -81.05% | - | - | - | - | Upgrade
|
| Free Cash Flow Margin | 0.16% | 0.90% | -22.11% | -36.86% | -21.63% | Upgrade
|
| Free Cash Flow Per Share | 0.01 | 0.06 | -1.40 | -2.42 | -1.41 | Upgrade
|
| Cash Income Tax Paid | 57.76 | 60.51 | 49.54 | 35.35 | 41.63 | Upgrade
|
| Levered Free Cash Flow | -68.78 | -89.72 | -244.19 | -461.11 | -246.11 | Upgrade
|
| Unlevered Free Cash Flow | -68.78 | -61.69 | -218.74 | -443.17 | -241.1 | Upgrade
|
| Change in Working Capital | -117.3 | -95.48 | -22.7 | -100.22 | -15.07 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.